Search results
Added:
1 month ago
Source:
Radcliffe CVRM
High-sensitivity C-reactive protein (hsCRP), a marker of inflammation, has a debated role in primary cardiovascular (CV) prevention. A large, population-based study using UK Biobank data has provided further insight into its utility as a clinical biomarker for identifying individuals at residual risk who do not have known atherosclerotic cardiovascular disease (ASCVD).¹MethodologyThis population…
View more
Added:
2 months ago
Source:
Arrhythmia Academy
Artificial intelligence applied to electrocardiograms (ECG-AI) may offer a scalable way to identify individuals at high risk of developing heart failure (HF), potentially improving on current clinical risk estimators, according to a new pooled cohort analysis from the HeartShare/Accelerating Medicines Partnership (AMP) Heart Failure program.¹The study aimed to assess whether ECG-AI models…
View more
Added:
9 months ago
Source:
Radcliffe CVRM
A new multi-ancestry polygenic score (PGS) for body mass index (BMI), developed using genetic data from over 5.1 million people, substantially improves the prediction of obesity across the life course compared to previous scores.¹ The research, which drew data from the GIANT consortium and 23andMe, demonstrates particular value in predicting obesity risk from early childhood and in understanding…
View more
Added:
6 months ago
TCT 2025 - 10-year findings from NOBLE showed no safety concerns for percutaneous coronary intervention (PCI) compared to coronary artery bypass surgery (CABG) for the treatment of left main coronary artery (LMCA) disease.Dr Evald Høj Christiansen (Aarhus University Hospital, Aarhus, DK) joins us to share the 10-year mortality findings from the NOBLE trial, investigating PCI vs CABG in LMCA…
View more
Added:
1 year ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further…
View more
Added:
1 month ago
ACC.26 – Dr Michael McConnell (Stanford Health Care, Stanford, CA, US) joins us to discuss findings from a prospective, multicentre clinical trial evaluating whether artificial intelligence analysis of retinal images can identify patients at elevated atherosclerotic cardiovascular risk.Findings showed strong sensitivity and specificity in identifying those at risk of ASCVD in a diverse study…
View more
Added:
1 month ago
ACC 2026 — Prof Divaka Perera (Guy's & St Thomas' Hospital and King's College London, UK) joins us to discuss findings from the CHIP-BCIS3 trial, examining the role of percutaneous left ventricular unloading in patients undergoing high-risk coronary intervention.This phase 3 randomised controlled trial enrolled 300 patients with severe left ventricular dysfunction and extensive coronary artery…
View more
Added:
1 year ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical…
View more
Added:
3 months ago
In this episode of Arrhythmia Academy's Journal Club, Dr David Duncker (Hannover Heart Rhythm Center, DE) is joined by Dr Marat Fudim (Duke University, US) to examine the critical early-risk period following heart failure diagnosis and the emerging role of wearable cardioverter defibrillators in sudden cardiac death prevention.The discussion centres on findings from the SCD-PROTECT study, a 19…
View more
Added:
2 months ago
Source:
Radcliffe Vascular
A post hoc analysis of the PROMISE trial has found that quantitative coronary plaque measures derived from coronary computed tomographic angiography (CCTA) can independently predict major adverse cardiovascular events (MACE) in symptomatic patients without a known history of coronary artery disease (CAD).¹ The findings suggest that total plaque burden and noncalcified plaque burden may enhance…
View more